[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648279":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":36,"responsibleParty":59,"collaborators":20,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":20,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":20,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":82,"whyStopped":20,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"West Virginia University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment","EXPERIMENTAL","FUS Neuromodulation",[13],"Device: Focused Ultrasound",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Focused Ultrasound","Subjects will undergo a single focused ultrasound Neuromodulation of the target brain region",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Ali Rezai","WVU Rockefeller Neuroscience Institute","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Marc Haut, PhD","CONTACT","304-293-8182","mhaut@hsc.wvu.edu",{"name":33,"role":29,"phone":34,"phoneExt":20,"email":35},"Jennifer Marton, BA","304-293-5886","jmarton@hsc.wvu.edu",[37],{"facility":24,"status":20,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Morgantown","West Virginia","26505","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-79.9559,39.62953,{"lat":47,"lon":46},[50,54,57],{"name":51,"role":29,"phone":52,"phoneExt":20,"email":53},"Victor Finomore, PhD","3042760500","vfinomore@hsc.wvu.edu",{"name":55,"role":29,"phone":52,"phoneExt":20,"email":56},"Padma Tirumalai, PhD","ptirumalai@hsc.wvu.edu",{"name":28,"role":58,"phone":20,"phoneExt":20,"email":20},"SUB_INVESTIGATOR",{"type":25,"investigatorFullName":23,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Executive Chair and Director","100648279","neuromodulation-for-behavioral-changes-in-neurological-disorders-100648279",false,"NCT07718906","Neuromodulation for Behavioral Changes in Neurological Disorders","A Prospective Early Feasibility Study of Focused Ultrasound Neuromodulation for Emotional Dysregulation Due to Dementia.","* Age 45-80 years at time of enrollment.\n* Diagnosis of probable mild-stage neurodegenerative dementia, including Alzheimer's disease (AD), frontotemporal dementia (FTD, including behavioral variant and language variant), or dementia with Lewy bodies (LBD), based on established consensus clinical criteria.\n* Presence of clinically meaningful (in treatment for or recommended for the symptoms) neuropsychiatric or behavioral symptoms including but not limited to anxiety, agitation, depression, irritability, apathy, or disinhibition\n* Able to undergo MRI scanning\n* Adequate auditory and visual abilities to complete study procedures as determined by the investigator.\n* Availability of a study partner (legally authorized representative, caregiver, or family member) who has regular contact with the participant and can provide collateral information and assist with assessments.\n* Ability to provide informed consent, or assent with legally authorized representative (LAR) consent in accordance with WVU IRB policy and applicable West Virginia law. .Currently under the care of a licensed physician, psychiatrist, or neurologist, and agrees to allow communication between investigators\u002Fstudy staff and healthcare providers for purposes of eligibility confirmation and safety monitoring.\n\nEXCLUSION CRITERIA\n\n* Moderate to severe dementia (i.e., beyond mild stage).\n* Clinically significant MRI abnormality that may jeopardize participant safety, study conduct, or confound diagnostic assessments.\n* History of clinically significant neurological disorder other than the qualifying dementia diagnosis that could confound evaluation or increase risk.\n* Major psychiatric disorder that would interfere with participation or safety, including psychosis, active suicidal ideation, or severe mood\u002Fanxiety disorder requiring immediate intervention.\n* Elevated suicide risk with History of medically verified suicide attempt within the past year.\n* Use of medications that significantly lower the seizure threshold or interfere with neuromodulation safety, as determined by the study physician.\n* Use of investigational drugs or participation in another interventional clinical trial within 30 days prior to screening.\n* Any condition that, in the opinion of the investigator, would interfere with study participation, safety, or interpretation of results.","ALL","45 Years","80 Years",{"count":72,"type":73},15,"ESTIMATED","INTERVENTIONAL",[76],"NA","The purpose of this study is to see if a focused ultrasound neuromodulation can be safely and effectively used to treat symptoms of emotional dysregulation such as agitation, irritability and anxiety",[79],"Dementia",[81,17],"Neuromodulation","NOT_YET_RECRUITING","2026-07-16",{"date":85,"type":86},"2026-07-22","ACTUAL",{"date":88,"type":73},"2026-07-25",{"date":90,"type":73},"2028-12-30",{"name":5,"class":6},1]